Health Care · S&P 500
Viatris
Viatris is a global generics-focused pharmaceutical company formed by the merger of Mylan and Pfizer's Upjohn. S&P 500 constituent. Sector: Health Care (Pharmaceuticals). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
VTRS Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21-26.1%'22-14.3%'23+2.1%'24+19.7%'25+5.1%YTD+32.8%
Money in ▸·
Viatrisapprox. $14.7B
▸ Money out·
Financials & Segments
- Total revenue · approx. $14.7B (FY2024)
- Segments · Developed Markets · Emerging Markets · Greater China
Revenue from
No refined links yet.
Pays to
No refined links yet.